These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 24072245

  • 1. Golden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone.
    Demirsoy U, Karadogan M, Selek Ö, Anik Y, Aksu G, Müezzinoglu B, Corapcioglu F.
    J Pediatr Hematol Oncol; 2014 Mar; 36(2):156-8. PubMed ID: 24072245
    [Abstract] [Full Text] [Related]

  • 2. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
    Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, Jun S, Jacobs I.
    Clin Cancer Res; 2012 Aug 15; 18(16):4415-24. PubMed ID: 22711702
    [Abstract] [Full Text] [Related]

  • 3. Denosumab: a new treatment option for giant cell tumor of bone.
    Lewin J, Thomas D.
    Drugs Today (Barc); 2013 Nov 15; 49(11):693-700. PubMed ID: 24308016
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
    Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I.
    Lancet Oncol; 2013 Aug 15; 14(9):901-8. PubMed ID: 23867211
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
    Takeuchi A, Tsuchiya H, Ishii T, Nishida Y, Abe S, Matsumine A, Kawai A, Yoshimura K, Ueda T.
    BMC Musculoskelet Disord; 2016 Jul 22; 17():306. PubMed ID: 27448567
    [Abstract] [Full Text] [Related]

  • 6. Denosumab: Excellent response of metastatic giant cell tumor of the bone.
    Ulas A, Bulent Akinci M, Silay K, Sendur MA, Sener Dede D, Yalcin B.
    J BUON; 2015 Jul 22; 20(2):666-7. PubMed ID: 26011370
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
    Gossai N, Hilgers MV, Polgreen LE, Greengard EG.
    Pediatr Blood Cancer; 2015 Jun 22; 62(6):1078-80. PubMed ID: 25556556
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Giant Cell Tumor of Bone: An Update.
    Basu Mallick A, Chawla SP.
    Curr Oncol Rep; 2021 Mar 22; 23(5):51. PubMed ID: 33754215
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Giant cell tumour of bone in the denosumab era.
    van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H.
    Eur J Cancer; 2017 May 22; 77():75-83. PubMed ID: 28365529
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The clinical approach toward giant cell tumor of bone.
    van der Heijden L, Dijkstra PD, van de Sande MA, Kroep JR, Nout RA, van Rijswijk CS, Bovée JV, Hogendoorn PC, Gelderblom H.
    Oncologist; 2014 May 22; 19(5):550-61. PubMed ID: 24718514
    [Abstract] [Full Text] [Related]

  • 18. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
    Sano K, Suehara Y, Okubo T, Sasa K, Kurihara T, Akaike K, Kubota D, Torigoe T, Hasegawa N, Ishii M, Nakamura Y, Kim Y, Takagi T, Kaneko K, Hayashi T, Saito T.
    J Orthop Surg (Hong Kong); 2020 May 22; 28(2):2309499020929786. PubMed ID: 32539628
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
    Traub F, Singh J, Dickson BC, Leung S, Mohankumar R, Blackstein ME, Razak AR, Griffin AM, Ferguson PC, Wunder JS.
    Eur J Cancer; 2016 May 22; 59():1-12. PubMed ID: 26990281
    [Abstract] [Full Text] [Related]

  • 20. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
    Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S.
    Lancet Oncol; 2010 Mar 22; 11(3):275-80. PubMed ID: 20149736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.